Is Praxbind still under exclusivity, and for how long?
Praxbind (idarucizumab) received FDA approval in 2015 as a targeted reversal agent for dabigatran. Public information provided here does not state Praxbind’s current patent or market exclusivity expiration dates, so the exact exclusivity status (and end date) can’t be confirmed from these sources alone.
What exclusivity type usually applies to Praxbind (and what to check)?
For drugs like Praxbind, “exclusivity” can come from different legal mechanisms, and the relevant end date depends on which applies. Common items to check include:
- Patent expiration (including any “listed” Orange Book patents that may block generic or biosimilar competition).
- FDA exclusivity periods (such as exclusivity tied to new active ingredients or changes), which can delay generic entry even if some patents expire.
Because no Orange Book, patent, or FDA exclusivity dates are included in the provided information, a definitive status and timeline can’t be stated.
How to confirm Praxbind’s exact exclusivity status quickly
To determine the current exclusivity status for Praxbind, the most direct approach is to look up:
- The FDA’s Orange Book entry for Praxbind to see “expiration” dates for patents listed for the product.
- FDA exclusivity data in connection with the same product (if separately listed).
If you share the strength/pack size (or the specific NDC) and the country (US vs. EU), I can help you map what to look for and how to interpret it.
Has Praxbind exclusivity been challenged or changed?
Exclusivity can shift in practice due to:
- Patent litigation or settlements affecting launch timing
- Revisions to listed patents or exclusivity determinations
- New competitors or authorized alternatives
No challenge or updated status details are included in the information available here, so I can’t verify whether exclusivity has been contested or altered.
If exclusivity ends, what would be the next practical milestone?
If exclusivity/patents expire, the next step is typically:
- Generic entry (if the product is eligible) or an authorized alternative, depending on the product’s regulatory pathway.
- Launch timing then follows the first permitted marketing date based on the controlling patents/exclusivity.
A precise “next milestone” date again requires the specific expiration data.
What I need to give you the exact “exclusivity status” answer
Tell me either:
- The US (or other country) focus, plus the NDC/strength you care about, or
- The FDA Orange Book link/entry text you’re using,
and I can translate that into a clear statement of Praxbind’s exclusivity status and the controlling expiration date(s).
Sources
No sources were provided in your prompt.